Quick Facts

• Assists with temporary relief of: Cough
• Assists with temporary relief of: Nasal congestion
• Assists with temporary relief of: Chest congestion/mucus

---

Robitussin Cough & Cold CF is a combination product used for the temporary relief of symptoms associated with the common cold, the flu, or allergies. This product contains a blend of active components intended to address three main areas.

First, it includes an ingredient that helps manage the urge to cough that results from minor throat and bronchial irritation. Second, the product contains an ingredient that may assist in loosening and thinning mucus or phlegm in the airways. This action contributes to making coughs more productive and facilitates the clearing of bronchial secretions.

Finally, the medication contains an active agent classified as a decongestant. This ingredient works to temporarily relieve nasal stuffiness and congestion in the nasal passages.

The eligibility to use Robitussin Cough & Cold CF is strictly defined by regulatory guidelines based on age, concurrent medications, and pre-existing health conditions.

Populations for whom use is Contraindicated

The medicine must not be used by children under 4 years of age. It is also strictly prohibited for any patient currently taking, or who has stopped taking within the last two weeks, a prescription Monoamine Oxidase Inhibitor (MAOI) drug.

---

Conditional Use Restrictions

Use is restricted and requires mandatory consultation with a health professional prior to administration if the individual has specific comorbidities, including heart disease, high blood pressure, thyroid disease, diabetes, or trouble urinating due to an enlarged prostate gland. Consultation is also required for pregnant or breast-feeding individuals and for those with a chronic cough or a cough that produces an excessive amount of phlegm.

---

Approved Age Eligibility

The product is approved for use in adults and children 12 years of age and over. Children between the ages of 4 and 12 years are eligible for use only with appropriate, regulated pediatric formulations.

Interaction Map: Interactions with other medicines and products — official regulatory information for Robitussin Cough & Cold CF

Interaction scope

• Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs), Strong CYP2D6 Inhibitors, Other Serotonergic Agents, Other Sympathomimetic Agents, Central Nervous System (CNS) Depressants, Oxytocic Drugs.
• Specific interacting medicines (if explicitly listed): Strong inhibitors of the CYP2D6 enzyme, such as Bupropion, Fluoxetine, Paroxetine, and Quinidine, are cited in regulatory documents.
• Mechanistic basis of interactions (only if stated in label): Inhibition of the enzyme CYP2D6 (pharmacokinetic); Additive Sympathomimetic Effects (pharmacodynamic); Additive Serotonergic Activity (pharmacodynamic).
• Timing-based interaction rules (if applicable): Mandatory separation of 14 days is required after the discontinuation of a Monoamine Oxidase Inhibitor (MAOI).
• Population-specific interaction notes (if applicable): Patients classified as CYP2D6 Poor Metabolizers are documented to naturally exhibit higher plasma concentrations of Dextromethorphan.
• Interaction-related restrictions: Co-administration with MAOIs is formally prohibited. The profile also documents interaction risks associated with alcohol and the herbal product St. John's wort.

---

Interaction classifications (high-level)

• Interaction severity classification (as defined in official documents): Contraindicated Combination (with MAOIs), Clinically Significant Interaction (with CYP2D6 Inhibitors), Interaction Increasing Side Effect Risk (with CNS Depressants).
• Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information, NIH MedlinePlus, DailyMed.
• Interaction-context constraints (as defined in official documents): The restriction with MAOIs applies regardless of the indication for which the MAOI was used.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated, and a 14-day mandatory separation window is required after MAOI discontinuation.
• Interactions with Strong CYP2D6 Inhibitors are documented to increase the plasma concentration (exposure) of Dextromethorphan.
• Co-administration with other serotonergic agents increases the risk of serotonin syndrome due to additive pharmacodynamic effects.
• Combination with other sympathomimetic agents or oxytocic drugs may lead to additive pressor effects (increased blood pressure).
• Consumption of alcohol and co-administration with other CNS depressants is documented to increase the risk of additive CNS side effects.
• CYP2D6 Poor Metabolizers exhibit a documented increase in systemic Dextromethorphan exposure compared to extensive metabolizers.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product’s interaction structure primarily through two lenses: absolute prohibition due to severe synergistic effects (MAOIs) and pharmacokinetic constraints involving the CYP2D6 enzyme system. The official profile lists multiple drug classes whose co-administration may lead to pharmacodynamic reinforcement, such as additive effects on the central nervous system and the cardiovascular system. This structured documentation exclusively details necessary constraints based on official regulatory findings.

How Robitussin Cough & Cold CF Works: The Biological Mechanisms

This medication modulates three distinct biological domains through targeted pharmacodynamic mechanisms.

Central Suppression of the Cough Reflex

The component Dextromethorphan acts as an agonist at the Sigma sigma 1 opioid receptor located in the brain's medullary cough center. This interaction dampens the sensitivity and activity of the central reflex circuit, resulting in an altered frequency and magnitude of the cough reflex output.

Peripheral Modulation of Respiratory Secretions

The expectorant, Guaifenesin, works peripherally by triggering a systemic reflex, potentially via gastric vagal receptors, which subsequently stimulates the bronchial glands. This reflex increases the volume and reduces the viscosity of respiratory secretions, leading to a physiochemical alteration of secretions that supports the physiological capacity for mobilization of tracheobronchial secretions.

Vasoconstriction and Nasal Airway Regulation

The decongestant, Pseudoephedrine, is an agonist of alpha-adrenergic receptors on the smooth muscle of nasal blood vessels. This action initiates local vasoconstriction, reducing blood flow and fluid leakage, which results in decreased nasal mucosal volume and reduced vascular permeability, establishing a key local physiological adjustment to the nasal passages.

The administration of Robitussin Cough & Cold CF is based on established parameters. This combination product, which contains Dextromethorphan HBr, Guaifenesin, and Phenylephrine HCl, is used via the oral route of administration as an oral liquid solution. The protocol establishes the standardized dose and frequency required for use.

The standard single dose is 20 milliliters (mL). This volume delivers a fixed combination of active ingredients, typically Dextromethorphan HBr 20 mg, Guaifenesin 400 mg, and Phenylephrine HCl 10 mg. Administration is scheduled every 4 hours as needed, but this must not exceed a maximum of 6 doses within any 24-hour period.

---

Procedural and Population Rules

Accurate administration requires measurement only with the dosing cup that is provided in the product packaging. This procedural control is essential to prevent exceeding the designated dose limits.

The product regimen is specified for use in Adults and children 12 years of age and over. This formulation is not for use in children under 12 years of age. The medicine is intended for short-term use, and use should be discontinued if symptoms persist for more than 7 days.

This structured approach—defining the precise route, fixed quantity, controlled frequency, and duration—ensures adherence to the use protocol.

Research Evidence / Overview of Studies for Robitussin Cough & Cold CF

---

Research Evidence for Non-Productive Cough Relief

The research exploring the component (Dextromethorphan) has primarily been conducted using short-term randomized controlled trials (RCTs). These studies were designed to monitor and measure outcomes related to physical discomfort, specifically examining how symptoms change over time for acute, non-productive coughs associated with respiratory illnesses. Findings describe patterns observed in the studies related to changes in the urge to cough over defined intervals, typically up to seven days. However, the evidence is limited, and findings were mixed across some studies regarding the consistency of the measured changes. There is limited information for long-term outcomes or for coughs that persist beyond the typical acute phase of a cold.

---

Research Evidence for Chest Congestion and Mucus

Research involving the expectorant component (Guaifenesin) explored conditions characterized by fluctuating manifestations, specifically chest congestion. Specialized expectorant trials examined how outcomes change in relation to this component by monitoring objective outcomes related to the thickness and volume of mucus, alongside patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the populations studied. The key limitation is that evidence quality varies across studies, and significant reliance is often placed on subjective measures of congestion. Data for certain groups remain insufficient, particularly in some age categories of children.

---

Research Evidence for Nasal Congestion

Research involving the nasal decongestant component (Phenylephrine) was conducted in studies using both single-dose and multiple-dose RCTs. Studies monitored changes in Nasal Airway Resistance (NAR) and patient-reported scores of nasal congestion. Findings indicate that the results were mixed and often non-significant when comparing the component's evaluation against a placebo in these trials. Certainty remains low regarding the research base for the component in relieving a stuffy nose. The primary limitation is that the existing evidence is insufficient to fully support the component's evaluation at its currently approved oral dosage, as noted by major regulatory advisory bodies.

---

Research Gaps and Uncertainties

Research highlights that the evidence for the nasal decongestant component is subject to regulatory uncertainty, which affects the overall evidence review of the multi-symptom product. Furthermore, data for certain groups remain insufficient, particularly research examining patient-reported experiences in very young children or those with complex, pre-existing health conditions. Sample sizes were modest in some earlier trials, and follow-up durations are generally limited to the short-term course of an acute cold.

Key Studies & References

1. DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE - DailyMed (FDA-Approved Labeling/Monograph)
2. FDA advisers say oral phenylephrine is not effective as a nasal decongestant (Nonprescription Drugs Advisory Committee Meeting 2023 Summary)

Common questions about Robitussin Cough & Cold CF (FAQ)

---

Q: What does CF stand for in the product name?

While not a medical or regulatory term, 'CF' in the product name is an abbreviation commonly used in the context of over-the-counter cold relief. It is generally understood to indicate a multi-symptom Cough and Cold Formula, highlighting its use for concurrent symptoms.

---

Q: Can Robitussin Cough & Cold CF help with a sore throat?

Official product information states that this formulation is primarily intended for the temporary relief of cough, chest congestion, and nasal congestion. Sore throat relief is not listed as a primary purpose of the specific active ingredient combination in this CF product. Regulatory labeling advises patients to choose a product that targets all their primary symptoms.

---

Q: How long does the relief from Robitussin Cough & Cold CF last?

The recommended dosing frequency for the product is established every four hours as needed, which defines the period between administrations. Patients should follow the official directions for administering the medicine.

---

Q: Is Robitussin Cough & Cold CF generally considered a daytime or nighttime formula?

According to the official product information, Robitussin Cough & Cold CF is generally described as a non-sedating option. The official side effect profile lists effects such as sleeplessness (insomnia), which is consistent with a non-sedating profile.

---

Q: Does Robitussin Cough & Cold CF cause drowsiness?

The formulation is officially marketed as a non-sedating option. While not classified as a common side effect, official documents do list dizziness as a potential effect. The reported side effects for this product do not commonly include drowsiness.

---

Q: Why does Robitussin CF sometimes make me feel restless or jittery?

The product label lists nervousness as a potential side effect. This effect is commonly reported by users and is associated with the stimulant properties of the Phenylephrine component, which acts as a nasal decongestant.

---

Q: Why do official documents mention the risk of nervousness?

Nervousness is listed in official documents as a common adverse reaction. This side effect is generally attributed to the stimulating properties of the Phenylephrine component, which functions as a nasal decongestant.

---

Q: Is it normal to feel a headache after taking Robitussin Cough & Cold CF?

Headache is generally not listed in official documents as a common, expected side effect. Instead, the label advises users to stop use and consult a health professional if a cough returns or occurs with a persistent headache, as this may be a signal of a more serious condition.

---

Q: What should I do if I miss a dose of Robitussin Cough & Cold CF?

General instructions for managing a missed dose state that it may be taken when remembered, provided it is not close to the time of the next scheduled dose. If it is nearly time for the next dose, the missed dose should be skipped. Official guidelines advise against exceeding the total daily dose.

---

Q: Why is careful reading of the label emphasized for this product?

Careful reading of the label is emphasized in regulatory guidance due to the presence of multiple active ingredients. It is necessary to identify potential for serious drug interactions, such as with MAOIs, and to strictly adhere to the requirement not to exceed the maximum recommended dose.

---

Q: What are the different forms Robitussin CF is sold in (e.g., liquid vs. gelcaps)?

The primary form detailed in regulatory information for this specific combination product is an oral liquid solution. While other formulas under the broader Robitussin brand name may be available in tablets or gelcaps, this specific CF combination is detailed as a liquid.

---

Q: Does Robitussin Cough & Cold CF contain any NSAIDs?

According to the official active ingredients list, the product contains Dextromethorphan HBr, Guaifenesin, and Phenylephrine HCl. It does not contain any ingredients classified as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen.

---

Q: Does Robitussin Cough & Cold CF contain alcohol?

Official listings of inactive ingredients for the liquid solution should be reviewed to confirm the presence of alcohol. Patients who wish to avoid alcohol should check the specific package label of the formulation.

---

Q: Can I use Robitussin Cough & Cold CF if I'm trying to avoid sugar?

Official labeling for the liquid formulation may or may not list sugar as an inactive ingredient; some formulas may use sugar substitutes. Patients who are avoiding sugar should check the inactive ingredient list on the specific product label for information on sweeteners.

---

Q: Is Robitussin Cough & Cold CF gluten-free?

The presence of gluten is not universally addressed on all product labels. However, certain Robitussin formulations have been explicitly labeled by the manufacturer as gluten-free. Patients with sensitivities rely on reviewing the ingredient list on their specific product.

---

Q: Can I take Robitussin Cough & Cold CF if I am taking Tylenol (acetaminophen)?

This Robitussin CF formulation does not contain acetaminophen. Regulatory guidance emphasizes that users should read the labels of all over-the-counter products to ensure the maximum daily dose of any shared ingredient, including acetaminophen, is not exceeded.

---

Q: Can I take Robitussin Cough & Cold CF with caffeine?

Official labeling contains a general precaution against using the product with other stimulants, including oral nasal decongestants. Since this medicine contains Phenylephrine, combining it with caffeine may increase the risk of side effects like nervousness or sleeplessness.

---

Q: Why is the drug contraindicated for certain pre-existing conditions?

The contraindications are established in regulatory documents to manage specific health risks. For conditions such as heart disease and high blood pressure, the restrictions are primarily due to the potential for the decongestant component to increase blood pressure or heart rate.

---

Q: Why is Robitussin Cough & Cold CF sometimes restricted for people with thyroid issues?

The restriction for individuals with thyroid disease is due to the presence of the decongestant ingredient, Phenylephrine. This component belongs to a class of drugs that can have stimulating effects on the cardiovascular and other body systems. Individuals with this pre-existing condition are instructed to consult a health professional before use.

---

Q: Can I take Robitussin Cough & Cold CF if I have high blood pressure?

Individuals with high blood pressure are instructed in the official drug facts to ask a health professional before using this product. This caution is generally associated with the decongestant component, Phenylephrine, which can affect the cardiovascular system.

---

Q: Is it safe to use Robitussin Cough & Cold CF if I have diabetes?

Official product labeling states that individuals with diabetes must consult a health professional prior to using this medicine.

---

Q: Can Robitussin Cough & Cold CF be used for coughs associated with asthma?

Official drug facts state that individuals with a cough that is chronic, such as occurs with asthma, are instructed to consult a health professional before use. This is to ensure the cough is appropriately managed in the context of the lung condition.

---

Q: Can I use this product if I have a chronic lung condition?

Official drug facts state that individuals with a cough that lasts or is chronic, such as occurs with conditions like smoking, chronic bronchitis, or emphysema, are instructed to ask a health professional before use. This restriction ensures the cough is properly evaluated.

---

Q: Is it safe for a senior person to use this medicine?

The product is approved for use in individuals 12 years and over. However, information regarding older adults (seniors) notes that this population may be more sensitive to certain side effects, such as dizziness or trouble sleeping. Official guidance notes that consultation with a health professional is typically recommended for older individuals with pre-existing conditions.

---

Q: Why does the label warn about driving or operating machinery?

The warning on the label is a precaution established due to potential side effects. The product may cause effects such as dizziness or nervousness, which could temporarily affect an individual’s judgment or ability to safely perform skilled tasks.

---

Q: Is Robitussin Cough & Cold CF a narcotic?

The cough suppressant component, Dextromethorphan, is not classified as a controlled substance or narcotic under U.S. federal regulatory classification (DEA Schedule N).

---

Q: Is there a risk of dependence or addiction with the active ingredients?

Official drug profiles for the active ingredients emphasize the importance of following the recommended dose to prevent serious harm. While the product is not classified as a controlled substance, the misuse or abuse of Dextromethorphan is associated with potential risks.

Official Storage Requirements

Robitussin Cough & Cold CF oral liquid must be stored at a controlled room temperature between 20^circC and 25^circC (68^circF and 77^circF), as directed by official labeling. The product is explicitly labeled Do not refrigerate. It must be kept in the original container to maintain its integrity, and the dosing cup (if provided) should remain with the product. To ensure safety, the medicine must be stored out of the reach of children.

Disposal of Unused Medicine

Expired or unused medication should ideally be disposed of using a medication take-back program or community drug collection site. If a take-back program is unavailable, official health authority guidance recommends mixing the liquid with an unappealing substance, such as dirt or used coffee grounds, placing the mixture in a sealed container, and discarding it in the household trash. This procedure prevents accidental exposure.